Navigation Links
Small molecule could have big impact on cancer
Date:5/28/2013

Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.

In a study published online May 28 in the journal Nature Communications, Ahn and his colleagues at UT Southwestern Medical Center describe the rational design of the molecule, as well as laboratory tests that show its effectiveness at blocking the cancer-promoting function of proteins called androgen receptors.

Androgen receptors are found inside cells and have complex surfaces with multiple "docking points" where various proteins can bind to the receptor. Each docking point has a unique shape, so only a correctly shaped molecule will fit.

Androgen hormones, such as testosterone, are the primary molecules that bind to androgen receptors. Such binding sets off a chain of events that activates several different processes in the human body, including stimulating the development and maintenance of male characteristics.

Looking for a new approach to battle prostate cancer, Ahn and his colleagues keyed in on blocking a critical docking point on the androgen receptor.

"When a tumor is trying to grow, activation of this location provides what the tumor needs," Ahn said. "There are other surfaces on the androgen receptor that are free to continue working with their respective proteins and to continue functioning. We sought to block only one set of interactions that contribute to prostate cancer growth. That's why we thought our approach might lead to potent efficacy with fewer side effects."

Using computer-assisted molecular modeling, Ahn designed a helix-mimicking small molecule that fits precisely into a pocket on the androgen receptor that is associated with prostate cancer. Collaborating with senior study author Dr. Ganesh Raj, associate professor of urology at UT Southwestern and a specialist in treating urologic cancers, the researchers tested the compound in animal and isolated human tissue. Without exhibiting noticeable toxicity, the compound prevented the androgen receptor from recruiting its protein partners and it blocked the growth of prostate cancer cells.

"We have shown that our molecule binds very tightly, targeting the androgen receptor with very high affinity," Ahn said. "We also have confirmed that it inhibits androgen function in these cells, which is a promising finding for drug development. We showed that it does work through these mechanisms, and it is as effective in inhibiting the proliferation of prostate cancer cells as other compounds currently in clinical trials."

Ahn plans to continue his research to better understand how the small molecule and related compounds he developed work against cancer on a molecular level. He said much work is left to do before any potential drugs or treatment might be developed, but added "this is an exciting start."

About 239,000 men are expected to be diagnosed with prostate cancer in the U.S. in 2013 and about 30,000 will die of the disease, according to the American Cancer Society.


'/>"/>

Contact: Amanda Siegfried
amanda.siegfried@utdallas.edu
972-883-4335
University of Texas at Dallas
Source:Eurekalert

Related medicine news :

1. Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
4. Small neural focus groups predict anti-smoking ad success
5. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
6. Analysis Finds Clinical Trials Often Small, of Poor Quality
7. Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study
8. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
9. Infants cant distinguish between large and small groups
10. Blood test for pregnant women could predict risk of having dangerously small babies
11. B2B e Trader is Addressing the Critical Needs of Local Businesses by Lauching the New Shop Small Business Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / jteixeira@thenc.org , ... from their Fathers , Contrary to a father’s perception, ...
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... asset protection assistance to communities in North-Central West Virginia, is embarking on a ... at-risk boys in the area. , The Chestnut Mountain Ranch (CMR) is a ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
Breaking Medicine Technology: